The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Stem Cell Collection and Gene Transfer in Fanconi Anemia
Open accessAbstract
Fanconi anemia (FA) is a rare genetic syndrome characterized by progressive bone marrow failure (BMF), congenital anomalies, and a predisposition to malignancy. Successful gene transfer into hematopoietic stem cells (HSCs) could reverse BMF in this disease. We developed clinical trials to determine whether a sufficient number of CD34(+) stem cells could be collected for gene modification and to evaluate the safety and efficacy of HSC-corrective gene transfer in FA genotype A (FANCA) patients. Here, we report that FA patients have significant depletion of their BM CD34(+) cell compartment even before severe pancytopenia is present. However, oncoretroviral-mediated ex vivo gene transfer was efficient in clinical scale in FA-A cells, leading to reversal of the cellular phenotype in a significant percentage of CD34(+) cells. Re-infusion of gene-corrected products in two patients was safe and well tolerated and accompanied by transient improvements in hemoglobin and platelet counts. Gene correction was transient, likely owing to the low dose of gene-corrected cells infused. Our early experience shows that stem cell collection is well tolerated in FA patients and suggests that collection be considered as early as possible in patients who are potential candidates for future gene transfer trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The success of gene therapy approaches to FA in a clinical setting has been limited by a combination of factors, including the paucity of autologous CD34+ cells available as targets for gene correction, reservations about the use of cytoreductive therapy to “make space” for the autologous graft, and potentially defective engraftment of FA HSC following prolonged in vitro processing[33–35].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [35]
In the citing paper
“Despite considerable challenges related to the procurement of autologous CD34+ HSC/P, two clinical gene therapy trials involving a total of 7 patients with FANCA and FANCC mutations have been conducted and these studies established the feasibility of gammaretroviral gene transfer of FA genes into human hematopoietic progenitor cells[34,35].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [35]
In the citing paper
“In addition, the predicted selective advantage of genetically corrected HSC over FANC-deficient HSC has not been observed in either trial.”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [35]
In the citing paper
“However, broad inter-individual variability of efficacy exists in normal healthy subjects, patients pre-treated with chemotherapy, and patients with Fanconi anemia[34,35,69,81].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [35]
In the citing paper
“Thus, the target CD34+ cell dose of 2×106 per kg future weight was not obtained in any patient.”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [35]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry
Sutherland, D. R., Anderson, L., Keeney, M., Nayar, R., & Chin-Yee, I. H. (1996) · Journal of Hematotherapy · doi:10.1089/scd.1.1996.5.213 · Cited by 1,277
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationCorrection of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975
Broxmeyer, H. E., Orschell, C. M., Clapp, D. W., Hangoc, G., Cooper, S., Plett, P. A., Liles, W. C., Li, X., Graham-Evans, B., Campbell, T. B., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041385 · Cited by 970
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
Liles, W. C., Broxmeyer, H. E., Rodger, E., Wood, B. L., Hübel, K., Cooper, S. H., Hangoc, G., Bridger, G. J., Henson, G. W., Calandra, G., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0663 · Cited by 718
Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus
Miller, A. D., Garcia, J. V., von Suhr, N., Lynch, C. M., Wilson, C. A., & Eiden, M. (1991) · Journal of Virology · doi:10.1128/jvi.65.5.2220-2224.1991 · Cited by 627
A 20-year perspective on the International Fanconi Anemia Registry (IFAR)
Kutler, D. I., Singh, B., Satagopan, J., Batish, S. D., Berwick, M., Giampietro, P. F., Hanenberg, H., & Auerbach, A. D. (2003) · Blood · doi:10.1182/blood-2002-07-2170 · Cited by 618
Self-citationThe Fanconi Anemia/BRCA pathway: new faces in the crowdPreprint
Kennedy, R. D., & D’Andrea, A. D. (2005) · Genes & Development · doi:10.1101/gad.1370505 · Cited by 474
Modulation of hematopoietic stem cell homing and engraftment by CD26
Christopherson, K. W., Hangoc, G., Mantel, C. R., & Broxmeyer, H. E. (2004) · Science · doi:10.1126/science.1097071 · Cited by 452
Cited by
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells
Raya, Á., Rodríguez-Pizà, I., Güenechea, G., Vassena, R., Navarro, S., Barrero, M. J., Consiglio, A., Castellà, M., Río, P., Sleep, E., et al. (2009) · Nature · doi:10.1038/nature08129 · Cited by 708
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T. S., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 384
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 262
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Zamarin, D., & Palese, P. (2012) · Future Microbiology · doi:10.2217/fmb.12.4 · Cited by 262
Adeno-associated virus capsid assembly is divergent and stochastic
Wörner, T. P., Bennett, A. D., Habka, S., Snijder, J., Friese, O. V., Powers, T. W., Agbandje‐McKenna, M., & Heck, A. J. R. (2021) · Nature Communications · doi:10.1038/s41467-021-21935-5 · Cited by 230
Engineering microRNA responsiveness to decrease virus pathogenicity
Kelly, E. J., Hadac, E. M., Greiner, S. M., & Russell, S. J. (2008) · Nature Medicine · doi:10.1038/nm.1776 · Cited by 220
Oncolytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates
Wollmann, G., Özduman, K., & van den Pol, A. N. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824671c9 · Cited by 211
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. H. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 209
Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics
Bogliolo, M., & Surrallés, J. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.07.002 · Cited by 198
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
Wong, H. H., Lemoine, N. R., & Wang, Y. (2010) · Viruses · doi:10.3390/v2010078 · Cited by 184
Río, P., Navarro, S., Wang, W., Sánchez‐Domínguez, R., Pujol, R. M., Segovia, J. C., Bogliolo, M., Merino, E., Wu, N., Salgado, R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0550-z · Cited by 180
Measles Virus for Cancer Therapy
Russell, S. J., & Peng, K.-W. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70617-5_11 · Cited by 176
Why does the bone marrow fail in Fanconi anemia?
Garaycoechea, J. I., & Patel, K. J. (2013) · Blood · doi:10.1182/blood-2013-09-427740 · Cited by 175
Overcoming reprogramming resistance of Fanconi anemia cells
Müller, L., Milsom, M. D., Harris, C. E., Vyas, R., Brumme, K. M., Parmar, K., Moreau, L. A., Schambach, A., Park, I., London, W. B., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408674 · Cited by 144
Self-citationQiao, J., Kottke, T. J., Willmon, C. L., Galivo, F., Wongthida, P., Díaz, R. M., Thompson, J., Ryno, P. K., Barber, G. N., Chester, J. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1681 · Cited by 141
Schugar, R. C., Chirieleison, S. M., Wescoe, K. E., Schmidt, B., Askew, Y. S., Nance, J. J., Evron, J. M., Péault, B., & Deasy, B. M. (2009) · BioMed Research International · doi:10.1155/2009/789526 · Cited by 139
Doniņa, S., Strēle, I., Proboka, G., Auziņš, J., Alberts, P., Jonsson, B., Venskus, D., & Muceniece, A. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000180 · Cited by 138
Ebens, C. L., MacMillan, M. L., & Wagner, J. E. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1268048 · Cited by 112
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways
Naik, S., & Russell, S. J. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903170653 · Cited by 112
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
Green, A. M., & Kupfer, G. M. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.01.008 · Cited by 94
Stress and DNA repair biology of the Fanconi anemia pathway
Longerich, S., Li, J., Xiong, Y., Sung, P., & Kupfer, G. M. (2014) · Blood · doi:10.1182/blood-2014-04-526293 · Cited by 88
Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
Seif, A. E. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.04.005 · Cited by 88
Tulpule, A., Lensch, M. W., Miller, J. D., Austin, K. M., D’Andrea, A. D., Schlaeger, T. M., Shimamura, A., & Daley, G. Q. (2010) · Blood · doi:10.1182/blood-2009-10-246694 · Cited by 87
Emerging applications of riboswitches – from antibacterial targets to molecular tools
Machtel, P., Bąkowska‐Żywicka, K., & Żywicki, M. (2016) · Journal of Applied Genetics · doi:10.1007/s13353-016-0341-x · Cited by 82
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer
Stanford, M. M., & McFadden, G. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1415 · Cited by 82
Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice
Zhang, Q., Tang, W., Deater, M., Phan, N., Marcogliese, A. N., Li, H., Al-Dhalimy, M., Major, A. M., Olson, S. B., Monnat, R. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683490 · Cited by 81
Características biológicas das células-tronco mesenquimais
Bydlowski, S. P., Debes, A. A., Maselli, L. M. F., & Janz, F. D. L. (2009) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842009005000038 · Cited by 78
Gene Therapy for Fanconi Anemia: One Step Closer to the Clinic
Tolar, J., Becker, P. S., Clapp, D. W., Hanenberg, H., de Heredia, C. D., Kiem, H., Navarro, S., Qasba, P., Río, P., Schmidt, M., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.237 · Cited by 77
Li, Y., Shi, C., Yuan, J., Yang, Y., Li, J., Ma, J., Wu, X., Freund, M., Pollok, K. E., Hanenberg, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168138 · Cited by 68
The Inherited Bone Marrow Failure Syndromes
Chirnomas, S. D., & Kupfer, G. M. (2013) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2013.09.007 · Cited by 64
Fernández-García, M., Yañez, R. M., Sánchez‐Domínguez, R., Hernando-Rodríguez, M., Peces-Barba, M., Herrera, G., O’Connor, J., Segovia, J. C., Bueren, J. A., & Lamana, M. L. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0155-5 · Cited by 63
Yannaki, E., Karponi, G., Zervou, F., Constantinou, V., Bouinta, A., Tachynopoulou, V., Kotta, K., Jonlin, E. C., Papayannopoulou, T., Anagnostopoulos, Α., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.163 · Cited by 63
Miernikiewicz, P., Dąbrowska, K., Skaradziński, G., & Górski, A. (2010) · Archives of Microbiology · doi:10.1007/s00203-010-0559-7 · Cited by 62
Kanai, R., Wakimoto, H., Cheema, T. A., & Rabkin, S. D. (2010) · Future Oncology · doi:10.2217/fon.10.18 · Cited by 60
Alemany, R. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0951-7 · Cited by 59
Río, P., Navarro, S., Güenechea, G., Sánchez‐Domínguez, R., Lamana, M. L., Yañez, R., Casado, J. A., Mehta, P. A., Pujol, R. M., Surrallés, J., et al. (2017) · Blood · doi:10.1182/blood-2017-03-774174 · Cited by 59
Materials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 58
Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer
Nettelbeck, D. M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0291-1 · Cited by 58
Oncolytic viruses—immunotherapeutics on the rise
Keller, B. A., & Bell, J. C. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1453-9 · Cited by 57
Oncomodulation by human cytomegalovirus: novel clinical findings open new roads
Michaelis, M., Baumgarten, P., Mittelbronn, M. G. A., Driever, P. H., Doerr, H. W., & Cinatl, J. J. (2010) · Medical Microbiology and Immunology · doi:10.1007/s00430-010-0177-7 · Cited by 57
Nicoletti, E., Rao, G. R., Bueren, J. A., Río, P., Navarro, S., Surrallés, J., Choi, G., & Schwartz, J. D. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03954-2 · Cited by 56
Potential and clinical translation of oncolytic measles viruses
Robinson, S. I., & Galanis, E. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1288713 · Cited by 55
Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita
Goldman, F. D., Aubert, G., Klingelhutz, A. J., Hills, M., Cooper, S., Hamilton, W. S., Schlueter, A. J., Lambie, K., Eaves, C. J., & Lansdorp, P. M. (2008) · Blood · doi:10.1182/blood-2007-10-120204 · Cited by 55
Adenovirus vectors in hematopoietic stem cell genome editing
Li, C., & Lieber, A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13668 · Cited by 54
Gene therapy for monogenic disorders of the bone marrow
Ghosh, S., Thrasher, A. J., & Gaspar, H. B. (2015) · British Journal of Haematology · doi:10.1111/bjh.13520 · Cited by 53
Jacome, A., Navarro, S., Río, P., Yañez, R. M., González‐Murillo, Á., Lozano, M. L., Lamana, M. L., Sevilla, J., Olivé, T., de Heredia, C. D., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.26 · Cited by 51
Li, J., Kao, K., Li, L., Yang, T., Wu, C., Horng, Y.-M., Jia, W. W.-G., & Yang, C. (2013) · Virology Journal · doi:10.1186/1743-422x-10-241 · Cited by 50
González‐Murillo, Á., Lozano, M. L., Alvarez, L. A., Jacome, A., Almarza, E., Navarro, S., Segovia, J. C., Hanenberg, H., Güenechea, G., Bueren, J. A., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.141 · Cited by 49
Fanconi anemia and the underlying causes of genomic instability
Rageul, J., & Kim, H. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22358 · Cited by 47
Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition
Milletti, G., Strocchio, L., Pagliara, D., Girardi, K., Carta, R., Mastronuzzi, A., Locatelli, F., & Nazio, F. (2020) · Cancers · doi:10.3390/cancers12092684 · Cited by 47
Tolar, J., Adair, J. E., Antoniou, M. N., Bartholomae, C. C., Becker, P. S., Blazar, B. R., Bueren, J. A., Carroll, T., Cavazzana, M., Clapp, D. W., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.78 · Cited by 45
Self-citationKaneda, Y. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.510511 · Cited by 44
Oncolytic Viruses from the Perspective of the Immune System
Alemany, R., & Cascalló, M. (2009) · Future Microbiology · doi:10.2217/fmb.09.28 · Cited by 44
Zhang, X., Shang, X., Guo, F., Murphy, K., Kirby, M., Kelly, P. F., Reeves, L., Smith, F. O., Williams, D. A., Zheng, Y., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147090 · Cited by 44
Self-citationAdair, J. E., Waters, T., Haworth, K. G., Kubek, S., Trobridge, G. D., Hocum, J. D., Heimfeld, S., & Kiem, H. (2016) · Nature Communications · doi:10.1038/ncomms13173 · Cited by 43
Advances in Gene Therapy for Fanconi Anemia
Río, P., Navarro, S., & Bueren, J. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.124 · Cited by 42
Gene and Viral Therapy for Glioblastoma: A Review of Clinical Trials and Future Directions
Mohyeldin, A., & Chiocca, E. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182458b13 · Cited by 41
Physical modeling of interference enhanced imaging and characterization of single nanoparticles
Avcı, O., Adato, R., Ayça Yalçın, A., & Ünlü, M. S. (2016) · Optics Express · doi:10.1364/oe.24.006094 · Cited by 40
Brendel, C., Río, P., & Verhoeyen, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113711 · Cited by 40
Becker, P. S., Taylor, J. A., Trobridge, G. D., Zhao, X., Beard, B. C., Chien, S. S., Adair, J. E., Kohn, D. B., Wagner, J. E., Shimamura, A., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.62 · Cited by 40
Müller, L. U., Milsom, M. D., Kim, M.-O., Schambach, A., Schuesler, T., & Williams, D. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.67 · Cited by 32
Self-citationFanconi anaemia: new strategies
Dufour, C., & Svahn, J. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.63 · Cited by 37
Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish
Botthof, J. G., Bielczyk-Maczyńska, E., Ferreira, L., & Cvejic, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620631114 · Cited by 37
Río, P., Zubicaray, J., Navarro, S., Gálvez, E. H., Sánchez‐Domínguez, R., Nicoletti, E., Sebastián, E., Rothe, M., Pujol, R. M., Bogliolo, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01880-4 · Cited by 35
FANCL ubiquitinates β-catenin and enhances its nuclear function
Dao, K.-H. T., Rotelli, M. D., Petersen, C. L., Kaech, S., Nelson, W. D., Yates, J. E., Newell, A. E. H., Olson, S. B., Druker, B. J., & Bagby, G. C. (2012) · Blood · doi:10.1182/blood-2011-11-388355 · Cited by 33
Fanconi anemia: a signal transduction and DNA repair pathway.
Kupfer, G. M. (2013) · PubMed Central · Cited by 33
Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia
Müller, L. U. W., & Williams, D. A. (2009) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2009.03.010 · Cited by 31
Self-citationSi, Y., Pulliam, A. C., Linka, Y., Ciccone, S., Leurs, C., Yuan, J., Eckermann, O., Fruehauf, S., Mooney, S., Hanenberg, H., et al. (2008) · Blood · doi:10.1182/blood-2007-07-102947 · Cited by 28
Magnusson, M. K., Kraaij, R., Leadley, R. M., Ridder, C. M. A. D., van Weerden, W. M., van Schie, K. A., van der Kroeg, M., Hoeben, R. C., Maitland, N. J., & Lindholm, L. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.016 · Cited by 31
Increased red cell distribution width in Fanconi anemia: a novel marker of stress erythropoiesis
Sousa, R., Gonçalves, C., Guerra, I. C., Costa, E., Fernandes, A., Sucesso, M. D. B., Azevedo, J., Rodríguez, A., Rius, R., Seabra, C., et al. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0485-0 · Cited by 31
Zhang, Q., Deater, M., Schubert, K. M., Loza, L. I. M., Pelz, C., Sinclair, D. A., & Grompe, M. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.05.007 · Cited by 29
Milsom, M. D., Schiedlmeier, B., Bailey, J., Kim, M., Li, D., Jansen, M., Ali, A. M., Kirby, M., Baum, C., Fairbairn, L., et al. (2009) · Blood · doi:10.1182/blood-2008-09-180224 · Cited by 28
Self-citationAdvances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Río, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 28
Río, P., Meza, N. W., González‐Murillo, Á., Navarro, S., Alvarez, L. A., Surrallés, J., Castellà, M., Güenechea, G., Segovia, J. C., Hanenberg, H., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156356 · Cited by 26
Sevilla, J., Navarro, S., Río, P., Sánchez‐Domínguez, R., Zubicaray, J., Gálvez, E. H., Merino, E., Sebastián, E., Azqueta, C., Casado, J. A., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.001 · Cited by 25
Will, E., Bailey, J., Schuesler, T., Modlich, U., Balcik, B., Burzynski, B. B., Witte, D. P., Layh‐Schmitt, G., Rudolph, C., Schlegelberger, B., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300083 · Cited by 25
Self-citationThe RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis
Kaneda, Y. (2013) · OncoImmunology · doi:10.4161/onci.23566 · Cited by 23
Modification of mammalian reoviruses for use as oncolytic agents
van den Wollenberg, D. J. M., van den Hengel, S. K., Dautzenberg, I. J. C., Kranenburg, O., & Hoeben, R. C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903307370 · Cited by 22
Fanconi Anemia: Overview of the Disease and the Role of Hematopoietic Transplantation
Schifferli, A., & Kühne, T. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000374 · Cited by 22
Inflammation-Mediated Notch Signaling Skews Fanconi Anemia Hematopoietic Stem Cell Differentiation
Du, W., Amarachintha, S. P., Sipple, J., Schick, J. S., Steinbrecher, K. A., & Pang, Q. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203474 · Cited by 22
Gene therapy for β-thalassaemia: the continuing challenge
Yannaki, E., Emery, D. W., & Stamatoyannopoulos, G. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001626 · Cited by 21
Update on clinical gene therapy in childhood
Qasim, W., Gaspar, H. B., & Thrasher, A. J. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.108787 · Cited by 21
Kochneva, G. V., Sivolobova, G. F., Iudina, K. V., Babkin, I. V., Chumakov, P. M., & Sv, N. (2012) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416812010041 · Cited by 20
Rust, B. J., Becker, P. S., Chandrasekaran, D., Kubek, S., Peterson, C. W., Adair, J. E., & Kiem, H. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.002 · Cited by 19
Geiselhart, A., Lier, A., Walter, D., & Milsom, M. D. (2012) · Anemia · doi:10.1155/2012/265790 · Cited by 19
Sleeping Beauty‐mediated correction of Fanconi anemia type C
Hyland, K. A., Olson, E. R., Clark, K. J., Aronovich, E. L., Hackett, P. B., Blazar, B. R., Tolar, J., & McIvor, R. S. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1589 · Cited by 19
Domenech, C., Maillard, L., Rousseau, A., Guidez, F., Petit, L., Pla, M., Clay, D., Guimiot, F., Sanfilippo, S., Jacques, S., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.10.001 · Cited by 19
Telomere Dysfunction and Hematologic Disorders
Paiva, R. M. A., & Calado, R. T. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-397898-1.00006-2 · Cited by 18
Noguchi, K., Ikawa, Y., Takenaka, M., Sakai, Y., Fujiki, T., Kuroda, R., Chappell, M., Ghiaccio, V., Rivella, S., & Wada, T. (2023) · Journal of Virological Methods · doi:10.1016/j.jviromet.2023.114689 · Cited by 17
Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases
Bueren, J. A., & Auricchio, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.152 · Cited by 17
Gupta, A. O., Azul, M., Bhoopalan, S. V., Abraham, A., Bertaina, A., Bidgoli, A., Bonfim, C., Dezern, A. E., Li, J., Louis, C. U., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.002 · Cited by 17
Impairment of fetal hematopoietic stem cell function in the absence of Fancd2
Suzuki, S., Racine, R. R., Manalo, N. A., Cantor, S. B., & Raffel, G. D. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.11.006 · Cited by 17
FANCD2 and HES1 suppress inflammation‐induced PPARɣ to prevent haematopoietic stem cell exhaustion
Wu, L., Li, X., Lin, Q., Chowdhury, F. A., Mazumder, M. H. H., & Du, W. (2020) · British Journal of Haematology · doi:10.1111/bjh.17230 · Cited by 17
CXCR4 induction in hematopoietic progenitor cells from Fanca−/−, -c−/−, and -d2−/− mice
Skinner, A. M., O'Neill, S. L., Grompe, M., & Kurre, P. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.11.006 · Cited by 17
Current and emerging therapeutic strategies for Fanconi anemia
Shukla, P., Ghosh, K., & Vundinti, B. R. (2012) · The HUGO Journal · doi:10.1186/1877-6566-6-1 · Cited by 17
Adair, J. E., Chandrasekaran, D., Sghia-Hughes, G., Haworth, K. G., Woolfrey, A. E., Burroughs, L. M., Choi, G. Y., Becker, P. S., & Kiem, H. (2018) · Haematologica · doi:10.3324/haematol.2018.194571 · Cited by 16
Correction of Fanconi Anemia Mutations Using Digital Genome Engineering
Sipe, C. J., Kluesner, M. G., Bingea, S. P., Lahr, W. S., Andrew, A. A., Wang, M., DeFeo, A. P., Hinkel, T., Laoharawee, K., Wagner, J. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158416 · Cited by 16
Role of gene therapy in Fanconi anemia: A systematic and literature review with future directions
Shafqat, S., Tariq, E., Parnes, A. D., Dasouki, M., Ahmed, S. O., & Hashmi, S. K. (2021) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2021.02.001 · Cited by 15
Milsom, M. D., Lee, A. W., Zheng, Y., & Cancelas, J. A. (2009) · Haematologica · doi:10.3324/haematol.2008.004077 · Cited by 15
Self-citation
Metadata
- Authors
- Kelly, P. F., Radtke, S., Kalle, C. V., Balcik, B., Bohn, K., Mueller, R., Schuesler, T., Haren, M., Reeves, L., Cancelas, J. A., Leemhuis, T., Harris, R., Auerbach, A. D., Smith, F. O., Davies, S. M., & Williams, D. A.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- University of Cincinnati (US)
- Rockefeller University (US)
- Corresponding author
- Williams, David A
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 15
- Issue
- 1
- Pages
- 211-219
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2007940575
- Cited by
- 180
- References
- 46
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 7 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 8 · 2017: 9 · 2016: 13 · 2015: 9 · 2014: 6 · 2013: 15 · 2012: 16
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R37HL032987, R37 HL23987, R01HL081499)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- Fanconi anemia, FANCA, hematopoietic stem cells, CD34+ cell collection, ex vivo gene transfer, oncoretroviral vectors, bone marrow failure, stem cell depletion, clinical trial safety and efficacy
- MeSH terms
- Adolescent, Bone Marrow, Cell Separation, Child, Child, Preschool, Fanconi Anemia, Humans, Infant, Stem Cells, Genetic Therapy, DNA, Complementary, Antigens, CD34, Transgenes, Fanconi Anemia Complementation Group A Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
